Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15981301 | 0.94 | MAPT (0.53) | MEN1KMT2ACYP2D6ATMTRPV1 | |
| SCHEMBL15982278 | 0.94 | MAPT (0.53) | MEN1KMT2ACYP2D6ATMTRPV1 | |
| SCHEMBL14501838 | 0.94 | MAPT (0.53) | MEN1KMT2ACYP2D6ATMTRPV1 | |
| SCHEMBL12826601 | 0.92 | MEN1 (0.47) | MEN1KMT2ACYP2D6ATMTRPV1 | |
| SCHEMBL8918332 | 0.92 | NPC1 (0.47) | MEN1KMT2ACYP2D6ATMTRPV1 | |
| SCHEMBL20225724 | 0.91 | CD274 (0.54) | MEN1KMT2ACYP2D6ATMTRPV1 | |
| SCHEMBL462559 | 0.89 | LMNA (0.59) | MEN1KMT2ACYP2D6LMNAMAPT | |
| SCHEMBL92784 | 0.87 | TAAR1 (0.60) | MEN1KMT2ACYP2D6ALDH1A1MAPT | |
| SCHEMBL8255914 | 0.83 | TAAR1 (0.52) | CYP2D6ATMHPGDALDH1A1LMNA | |
| SCHEMBL6567451 | 0.80 | PARP1 (0.57) | MEN1KMT2ACYP2D6ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118922418-A | Tetrahydroisoquinoline derivatives serving as pan-KRAS inhibitor as well as preparation method and application thereof | 思路迪生物医药(上海)有限公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2024151833-A1 | SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF | CEREVEL THERAPEUTICS, LLC (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024112918-A1 | RNA DEGRADERS AND USES THEREOF | ARRAKIS THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2023169481-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AS PAN-KRAS INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 思路迪生物医药(上海)有限公司 | 2023-09-14 | — | — | WO | disclosed |
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| WO-2023148481-A1 | SMO MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2023-08-10 | — | — | WO | disclosed |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2023-07-06 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-11661421-B2 | Indolizine compounds, preparation method and use thereof | HAIHE BIOPHARMA CO., LTD. (CN) | 2023-05-30 | — | — | US | disclosed |
| WO-2023088167-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2023-05-25 | — | — | WO | disclosed |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ALZHEIMER'S INSTITUTE OF AMERICA, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070027158-A1 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-7169775-B2 | Amino methyl imidazoles as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20050159469-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2005-07-21 | — | — | US | disclosed |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6528532-B1 | Benzenesulfonamide group | PHARMACOR INC. (CA) | 2003-03-04 | — | — | US | disclosed |
| US-6528532-B1 | Benzenesulfonamide group | PHARMACOR INC. (CA) | 2003-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027158-A1 | High affinity small molecule C5a receptor modulators | C3AR1, C5AR1, C5AR2 | MEN1 4152/4885KMT2A 4117/4885CYP2D6 975/4885 |
| US-11661421-B2 | Indolizine compounds, preparation method and use thereof | EZH1, EZH2, IKZF3 | MEN1 266/4885KMT2A 49/4885CYP2D6 2991/4885 |
| US-11725000-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | MEN1 4080/4885KMT2A 3060/4885CYP2D6 581/4885 |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, PDE2A | MEN1 3926/4885KMT2A 2302/4885CYP2D6 619/4885 |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCC5, ABCC1 | MEN1 4838/4885KMT2A 4805/4885CYP2D6 537/4885 |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | MEN1 3556/4885KMT2A 3261/4885CYP2D6 1349/4885 |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | MEN1 3518/4885KMT2A 1139/4885CYP2D6 603/4885 |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | MEN1 4549/4885KMT2A 4002/4885CYP2D6 1384/4885 |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | MEN1 2917/4885KMT2A 4711/4885CYP2D6 4551/4885 |
| US-20050159469-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | MEN1 4515/4885KMT2A 4151/4885CYP2D6 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.